In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3320-3330

  Lopes De Menezes, Daniel E ^a   Pilarski, Linda M ^b   Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD19; B-LYMPHOCYTES; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTOXINS; LIPOSOMES; LYMPHOMA, B-CELL; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0001160175     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Foon, K. A., and Todd, R. F. III. Immunologic classification of leukemia and lymphoma. Blood, 68: 1-31, 1986.
2. Magrath, I. T., and Ziegler, J. L. Bone marrow involvement in Burkitt's lymphoma and its relationship to acute B-cell leukemia. Leuk. Res., 4: 33-59, 1979.
3. Griepp, P. R. Advances in the diagnosis and management of myeloma. Semin. Hematol., 29: 24-45, 1992.
4. Pilarski, L. M., and Jensen, G. S. Monoclonal circulating B cells in multiple myeloma: a continuously differentiating, possible invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol. Oncol. Clin. N. Am., 6: 297-322,1992.
5. Tyle, P., and Ram, B. P. Monoclonal antibodies, immunoconjugates, and liposomes as targeted therapeutic systems. Targeted Diagn. Ther. Ser., 3: 3-22, 1990.
6. Hakomori, S. Aberrant glycosylation on cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res., 45: 2405-2414, 1985.
7. Waldmann, T. A. Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. Annu. Rev. Immunol., 10: 675-704, 1992.
8. Vitetta, E. S., and Uhr, J. W. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res., 54: 5301-5309, 1994.
9. Ghetie, V., and Vitetta, E. Immunotoxins in the therapy of cancer: from bench to clinic. Pharmacol. Ther., 63: 209-234, 1994.
10. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellstrom, I., and Hellstrom, K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (Washington DC), 261: 212-215, 1993.
11. Larson, S. M., Macapinlac, H. A., Scott, A. M., and Divgi, C. R. Recent achievements in the development of radiolabelled monoclonal antibodies for diagnosis, therapy and biological characterization of human tumours. Acta Oncol., 32: 709-715, 1993.
12. Saltzman, W. M. Antibodies for treating and preventing diseases: the potential role of polymeric controlled release. Crit. Rev. Ther. Drug Carrier Syst., 10: 111-142, 1993.
13. Vingerhoeds, M. H., Storm, G., and Crommelin, D. J. Immunoliposomes in vivo. Immuno. Methods, 4: 259-272, 1994.
14. Allen, T. M., Ahmad, I., Lopes de Menezes, D. E., and Moase, E. H. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans., 23: 1073-1079, 1995.
15. Gabizon, A., Shiota, R., and Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst., 81: 1484-1488, 1989.
16. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C, Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
17. Allen, T. M., Mehra, T., Hansen, C. B., and Chin, Y. C. Stealth liposomes: an improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res., 52: 2431-2439, 1992.
18. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
19. Allen, T. M., Hansen, C. B., and Lopes de Menezes, D. E. Pharmacokinetics of long circulating liposomes. Adv. Drug Del. Rev., 16: 267-284, 1995.
20. Allen, T. M., and Hansen, C. B. Pharmacokinetics of Stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta, 1068: 133-141, 1991.
21. Allen, T. M., Hansen, C. B., Martin, F., Redemann, C., and Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1066: 29-36, 1991.
22. 1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett., 284: 263-266, 1991.
23. Woodle, M. C., Matthay, K. K., Newman, M. S., Hidayat, J. E., Collins, L. R., Redemann, C., Martin, F. J., and Papahadjopoulos, D. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta, 1105: 193-200, 1992.
24. Blume, G., and Cevc, G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta, 1146: 157-168, 1993.
25. Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., Amantea, M. A., and Kaplan, L. D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol., 36: 55-63, 1996.
26. Blume, G., Cevc, G., Crommelin, M. D., Bakker-Woudenberg, L. A., Kluft, C., and Storm, G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta, 1149: 180-184, 1993.
27. HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 92: 1327-1331, 1995.
28. Maruyama, K., Takizawa, T., Yuda, T., Kennel, S. J., Huang, L., and Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta, 1234: 74-80, 1995.
29. Zalipsky, S. Synthesis of end-group functionalized polyethylene glycol-lipid conjugates for preparation of polymer-grafted liposomes. Bioconjug. Chem., 4: 296-299, 1993.
30. Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., and Zalipsky, S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta, 1237: 99-108, 1995.
31. Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., and Allen, T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta, 1239: 133-144, 1995.
32. Ahmad, I., and Allen, T. M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res., 52: 4817-4820, 1992.
33. Ahmad, I., Longenecker, M., Samuel, J., and Allen, T. M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res., 53: 1484-1488, 1993.
34. Lee, R. J., and Low, P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta, 1233: 134-144, 1995.
35. Torchilin, V. P., Narula, J., Halpern, E., and Khaw, B. A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta, 1279: 75-83, 1996.
36. Hughes, B. J., Kennel, S., Lee, R., and Huang, L. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res., 49: 6214-6220, 1989.
37. Weinstein, J. N., and van Osdol, W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier." Cancer Res., 52: 2747-2751, 1992.
38. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res., 54: 3352-3356, 1994.
39. Pilarski, L. M., Cass, C. E., Tsuro, T., and Belch, A. R. Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Curr. Top. Microbiol. Immunol., 182: 177-185, 1992.
40. Pilarski, L. M., and Belch, A. R. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of multi-drug resistant disease in multiple myeloma. Blood, 83: 724-736, 1994.
41. Pilarski, L. M., and Belch, A. R. Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. Leuk. Lymphoma, 17: 367-374, 1995.
42. de Rie, M. A., Schumacher, T. N., van Schijndel, G. M., van Lier, R. A., and Miedema, F. Regulatory role of CD19 molecules in B-cell activation and differentiation. Cell. Immunol., 118: 368-381, 1989.
43. Uckun, F. M., Jaszcz, W., Ambrus, J. L., Fauci, A. S., Gajl-Peczalska, K., Song, S. W., Wick, M. R., Myers, D. E., Waddick, K., and Ledbetter, J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71: 13-29, 1988.
44. Ghetie, M. A., Picker, L. J., Richardson, J. A., Tucker, K., Uhr, J. W., and Vitetta, E. S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood, 83: 1329-1336, 1994.
45. Pizer, B. L., and Kemshead, J. T. The potential of targeted radiotherapy in the treatment of central nervous system leukemia. Leuk. Lymphoma, 15: 281-289, 1994.
46. Vervoordeldonk, S. F., Merle, P. A., van Leeuwen, E. F., von dem Borne, A. E., and Slaper-Cortenbach, I. C. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. Cancer (Phila.), 73 (Suppl.): 1006-1011, 1994.
47. Stone, M. J., Sausville, E. A., Fay, J. W., Headlee, D., Collins, R. H., Figg, W. D., Stetler Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J. W., and Vitetta, E. S. A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD-37-dgA, in patients with B-cell lymphoma. Blood, 88: 1188-1197, 1996.
48. Hekman, A., Honselaar, A., Vuist, W. M., Sein, J. J., Rodenhuis, S., Bokkel Huinink, W. W., Somers, R., Rumke, P., and Melief, C. J. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol. Immunother., 32: 364-372, 1991.
49. Grossbard, M. L., Freedman, A. S., Ritz, J., Coral, F., Goldmacher, V. S., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., Blattler, W. A., Taylor, J. A., and Nadler, L. M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood, 79: 576-585, 1992.
50. 125I-labelled inulin: a convenient marker for deposition of liposomal contents in vivo. Biochem. Biophys. Res. Commun., 122: 319-324, 1984.
51. Zola, H., MacArdle, P. J., Bradford, T., Weedon, H., Yasui, H., and Kurosawa, Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol., 69: 411-422, 1991.
52. Derksen, J. T., Morselt, H. W., and Scherphof, G. L. Processing of different liposomal markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim. Biophys. Acta. 931: 33-40, 1987.
53. Pool, G. L., French, M. E., Edwards, R. A., Huang, L., and Lumb, R. H. Use of radiolabelled hexadecyl cholesterol ether as a liposome marker. Lipids, 17: 445-452, 1982.
54. Olson, F., Hunt, C. A., Szoka, F. C., Vail, W. J., and Papahadjopoulos, D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta, 557: 9-23, 1979.
55. Mayer, L. D., Hope, M. J., and Cullis, P. R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta, 858: 161-168, 1986.
56. Bolotin, E. M., Cohen, R., Bar, L. K., Emanuel, S. N., Lasic, D. D., and Barenholz, Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome Res., 4: 455-479, 1994.
57. Bartlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem., 234: 466-468, 1959.
58. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
59. Allen, T. M., and Chonn, A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett., 223: 42-46, 1987.
60. Allen, T. M. Stealth liposomes: avoiding reticuloendothelial uptake. In: Liposomes in the Therapy of Infectious Disease and Cancer, UCLA Symposium in Molecular and Cellular Biology, pp. 405-415. Boca Raton, FL: CRC Press, 1984.
61. Ishiwata, H., Vertut-Doi, A., Hirose, T., and Miyajima, K. Physical chemistry characteristics and biodistribution of poly(ethyleneglycol)-coated liposomes using poly(oxyethylene) cholesteryl ether. Chem. Pharm. Bull. (Tokyo), 43: 1005-1011, 1995.
62. Huang, C., and Mason, J. T. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc. Natl. Acad. Sci. USA, 75: 308-310, 1978.
63. Blaurock, A. E. Evidence for bilayer structure and of membrane interactions from X-ray diffraction analysis. Biochim. Biophys. Acta, 650: 167-207, 1982.
64. Kenworthy, A. K., Simon, S. A., and McIntosh, T. J. Structure and phase behaviour of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). Biophys. J., 68: 1903-1920, 1995.
65. Miyajima, K., Lee, T., and Nakagaki, M. Micelle formation of polyoxyethylene cholesteryl ether in water. Chem. Pharm. Bull. (Tokyo), 32, 3670-3673, 1984.
66. Moore, M. S., Mahaffey, D. T., Brodsky, F. M., and Anderson, R. G. Assembly of clathrin-coated pits onto purified plasma membranes. Science (Washington DC), 236: 558-563, 1997.
67. Wolff, B., and Gregoriadis, G. The use of monoclonal anti-Thy1 IgG1 for the targeting of liposomes to AKR-A cells in vitro and in vivo. Biochim. Biophys. Acta, 802: 259-273, 1984.
68. Tedder, T. F., and Isaacs, C. M. Isolation of cDNA encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J. Immunol., 143: 712-717, 1989.
69. van Oosterhout, Y. V. J. M., van den Herik-Oudijk, I. E., Wessels, H. M. C., de Witte, T., van de Winkel, J. G. J., and Preijers, F. W. M. B. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res., 54: 3527-3532, 1994.
70. Press, O. W., Farr, A. G., Borroz, K. I., Andersen, S. K., and Martin, P. J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 49: 4906-4912, 1989.
71. Allen, T. M., Hansen, C. B., and Guo, L. S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochem. Biophys. Acta, 1150: 9-16, 1993.
72. Goulet, A. C., Goldmacher, V. S., Lambert, J. M., Baron, C., Roy, D. C., and Kouassi, E. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization an CD19 internalization. Blood, 90: 2364-2375, 1997.
73. Zalipsky, S., Hansen, C. B., Lopes de Menezes, D. E., and Allen, T. M. Long-circulating polyethylene glycol-grafted immunoliposomes. J. Control. Release, 39: 153-161, 1996.
74. Nicholson, I. C., Lenton, K. A., Little, D. J., DeCorso, T., Lee, F. T., Scott, A. M., Zola, H., and Hohmann, A. W. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukemia and lymphoma. Mol. Immunol., in press, 1998.
75. Lambert, J. M., Goldmacher, V. S., Collinson, A. R., Nadler, L. M., and Blattler, W. A. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res., 51: 6236-6242, 1991.
76. Torchilin, V. P., and Papisov, M. I. Why do polyethylene glycol-coated liposomes circulate so long? molecular mechanism of liposome steric protection with polyethylene glycol: role of polymer chain flexibility. J. Liposome Res., 4: 725-739, 1994.
77. Pilarski, L. M., Mant, M. J., Reuther, B. A., and Belch, A. R. Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J. Clin. Investig., 74: 1301-1305, 1984.
78. Bradley, G., and Ling, V. P-glycoprotein, multidrug resistance and tumour progression. Cancer Metastasis Rev., 13: 223-233, 1994.
79. Sumizawa, T., Chuman, Y., Sakamoto, H., Iemura, K., Almquist, K., C., Deeley, R. G., Cole, S. P., and Akiyama, S. Non-P-glycoprotein-mediated multidrug resistant human KB cells selected in medium containing Adriamycin, cepharantine and mezerein. Somat. Cell Mol. Genet., 20: 423-435, 1994.